Germany takes some pain out of new drug reimbursement
This article was originally published in SRA
Executive Summary
Companies wanting to make it through Germany's early benefit assessment system that was introduced under the AMNOG healthcare reform act will very soon have more freedom to choose which comparator their new drug must go up against in the system's tough benefit assessments. On 5 July, Germany's Bundesrat, the federal council, signed off changes which will come into effect within a few weeks.